Business Description
Lotus Pharmaceutical Co Ltd
ISIN : TW0001795003
Share Class Description:
TPE:1795: Ordinary SharesTotal Employee Number:
1,099Description
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 2 | |||||
Debt-to-EBITDA | 5.83 | |||||
Interest Coverage | 6.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.1 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.9 | |||||
3-Year EBITDA Growth Rate | 15.7 | |||||
3-Year EPS without NRI Growth Rate | 16 | |||||
3-Year FCF Growth Rate | 68.8 | |||||
3-Year Book Growth Rate | 19.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.28 | |||||
9-Day RSI | 71.04 | |||||
14-Day RSI | 62.39 | |||||
3-1 Month Momentum % | -9.7 | |||||
6-1 Month Momentum % | -31.88 | |||||
12-1 Month Momentum % | -6.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.57 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.46 | |||||
Days Inventory | 213.28 | |||||
Days Sales Outstanding | 115.88 | |||||
Days Payable | 54.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.79 | |||||
Dividend Payout Ratio | 0.32 | |||||
3-Year Dividend Growth Rate | 44.1 | |||||
Forward Dividend Yield % | 2.79 | |||||
5-Year Yield-on-Cost % | 2.83 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -12.54 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.05 | |||||
Operating Margin % | 28.75 | |||||
Net Margin % | 23.01 | |||||
EBITDA Margin % | 39.73 | |||||
FCF Margin % | 15.25 | |||||
OCF Margin % | 36.48 | |||||
ROE % | 21.71 | |||||
ROA % | 8.92 | |||||
ROIC % | 11.36 | |||||
3-Year ROIIC % | 2.48 | |||||
ROC (Joel Greenblatt) % | 59.26 | |||||
ROCE % | 15.6 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.64 | |||||
Forward PE Ratio | 13.5 | |||||
PE Ratio without NRI | 11.65 | |||||
Shiller PE Ratio | 24.21 | |||||
Price-to-Owner-Earnings | 9.43 | |||||
PEG Ratio | 0.39 | |||||
PS Ratio | 2.67 | |||||
PB Ratio | 2.32 | |||||
Price-to-Free-Cash-Flow | 17.51 | |||||
Price-to-Operating-Cash-Flow | 7.35 | |||||
EV-to-EBIT | 14.34 | |||||
EV-to-EBITDA | 11.63 | |||||
EV-to-Revenue | 4.61 | |||||
EV-to-FCF | 29.47 | |||||
Price-to-GF-Value | 0.47 | |||||
Price-to-Projected-FCF | 1.76 | |||||
Price-to-DCF (Earnings Based) | 0.37 | |||||
Price-to-DCF (FCF Based) | 0.56 | |||||
Price-to-Median-PS-Value | 0.95 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.47 | |||||
Earnings Yield (Greenblatt) % | 6.97 | |||||
FCF Yield % | 5.67 | |||||
Forward Rate of Return (Yacktman) % | 22.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lotus Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 20,509.474 | ||
| EPS (TTM) (NT$) | 18.01 | ||
| Beta | -0.7461 | ||
| 3-Year Sharpe Ratio | -0.29 | ||
| 3-Year Sortino Ratio | -0.41 | ||
| Volatility % | 63.32 | ||
| 14-Day RSI | 62.39 | ||
| 14-Day ATR (NT$) | 7.384882 | ||
| 20-Day SMA (NT$) | 194.825 | ||
| 12-1 Month Momentum % | -6.01 | ||
| 52-Week Range (NT$) | 182 - 369.5 | ||
| Shares Outstanding (Mil) | 262.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lotus Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lotus Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 5.778592 Cash Dividend | 2025-08-11 | 221.50 (-0.23%) | ||
| TWD 4.647452 Cash Dividend | 2024-08-05 | 260.00 (-3.53%) | ||
| 1.06:1 Stock Split | 2010-09-08 | 57.86 (+1.82%) | ||
| 1.05:1 Stock Split | 2009-08-12 | 11.51 (+0.00%) | ||
| 1.1:1 Stock Split | 2008-08-14 | -- | ||
| 1.04:1 Stock Split | 2005-09-12 | -- |
Show
Entries
Lotus Pharmaceutical Co Ltd Frequently Asked Questions
What is Lotus Pharmaceutical Co Ltd(TPE:1795)'s stock price today?
The current price of TPE:1795 is NT$209.50. The 52 week high of TPE:1795 is NT$369.50 and 52 week low is NT$182.00.
When is next earnings date of Lotus Pharmaceutical Co Ltd(TPE:1795)?
The next earnings date of Lotus Pharmaceutical Co Ltd(TPE:1795) is .
Does Lotus Pharmaceutical Co Ltd(TPE:1795) pay dividends? If so, how much?
The Dividend Yield %  of Lotus Pharmaceutical Co Ltd(TPE:1795) is 2.79% (As of Today), Highest Dividend Payout Ratio of Lotus Pharmaceutical Co Ltd(TPE:1795) was 0.32. The lowest was 0.06. And the median was 0.22. The  Forward Dividend Yield % of Lotus Pharmaceutical Co Ltd(TPE:1795) is 2.79%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Lotus Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers